l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine has been researched along with Parkinson Disease, Secondary in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (50.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Foster, AC; Hill, RG; Iversen, L; Iversen, SD; Kemp, JA; Leeson, PD; Rupniak, NM; Saywell, K; Tricklebank, MD; Williams, BJ | 1 |
Iversen, SD; Miyaji, M; Naruse, T; Rupniak, NM; Tye, SJ | 1 |
1 review(s) available for l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine and Parkinson Disease, Secondary
Article | Year |
---|---|
Neurotoxin-related research: from the laboratory to the clinic.
Topics: Animals; Antiparkinson Agents; Dopamine Agents; Humans; Levodopa; Mice; MPTP Poisoning; Nervous System; Neurotoxins; Oxazines; Parkinson Disease, Secondary; Prodrugs; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Saimiri | 1992 |
1 other study(ies) available for l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine and Parkinson Disease, Secondary
Article | Year |
---|---|
NB-355: a novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinson Disease, Secondary; Prodrugs; Saimiri; Time Factors | 1989 |